As antibiotic resistance continues to rise, researchers are exploring how modifying natural compounds like cannabigerol (CBG) can enhance their antibacterial effects. This study examined the structure–activity relationships (SAR) of CBG and its precursor cannabigerolic acid (CBGA) to understand how changes in their chemical structure impact their ability to fight Gram-positive bacteria. Scientists tested a range of modified cannabinoid compounds against bacteria such as Staphylococcus aureus, including drug-resistant strains, as well as Enterococcus faecalis and other clinically relevant pathogens.

The findings showed that several CBG and CBGA derivatives demonstrated potent antibacterial activity, in some cases comparable to established antibiotics. A key discovery was that the terpene portion of the molecule—specifically the length and structure of its carbon chain—played a critical role in determining antibacterial strength. Compounds with terpene chains between 6 and 13 carbons showed strong activity while remaining non-toxic to mammalian cells. These results suggest that carefully modifying this region of the molecule can significantly improve how effectively cannabinoids target bacteria.

Overall, the study highlights the potential of CBG-based compounds as next-generation antibacterial agents, particularly against Gram-positive and drug-resistant bacteria. Because this research was conducted in laboratory settings, further studies—including animal and human trials—are needed to determine safety, dosing, and clinical usefulness. Still, the findings provide a strong foundation for developing cannabinoid-derived antibiotics through targeted chemical design.

Source:
Mandal PS, et al. Structure–Activity Relationships of Cannabigerol and Cannabigerolic Acid Derivatives as Antibacterial Agents against Gram-Positive Bacteria. National Library of Medicine (NIH):
https://pmc.ncbi.nlm.nih.gov/articles/PMC13019258/